Reaction
Application Site Inflammation reporting signals
As of the last recalculation, Application Site Inflammation appears in 1,354 FAERS reports alongside 18 co-occurring drug terms. The strongest observed disproportionality signal is CRISABOROLE (PRR 45.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Crisaborole | 28 | 45.8 | 45.9 |
| Minoxidil Foam 5% (Womens) | 56 | 27.2 | 27.2 |
| Minoxidil | 72 | 26.0 | 26.0 |
| Glycerin, Lidocaine | 19 | 21.1 | 21.2 |
| Nicotine | 52 | 20.5 | 20.5 |
| Docosanol | 19 | 20.2 | 20.2 |
| Estradiol | 90 | 17.1 | 17.1 |
| Oxybutynin | 26 | 13.9 | 13.9 |
| Methylphenidate | 25 | 13.5 | 13.5 |
| Rivastigmine | 13 | 10.7 | 10.7 |
| Buprenorphine | 53 | 9.1 | 9.1 |
| Clobetasol Propionate Ointment Usp, 0.05% | 6 | 9.0 | 9.0 |
| Clobetasol Propionate | 6 | 9.0 | 9.0 |
| Estradiol Gel 0.1% | 25 | 8.6 | 8.6 |
| Estradiol Transdermal | 25 | 8.6 | 8.6 |
| Rotigotine | 7 | 7.5 | 7.5 |
| Nicotine Polacrilex | 15 | 6.1 | 6.1 |
| Adapalene | 4 | 0.3 | 0.3 |